FDA’s Animal Testing Phase-Out: A Regulatory Shift with Immediate Implications for Organoid Science

On April 10, 2025, the U.S. Food and Drug Administration announced a formal commitment to phase out animal testing requirements for preclinical safety studies, beginning with monoclonal antibodies and expanding to other drug types. The accompanying “Roadmap to Reducing Animal Testing in Preclinical Safety Studies” marks the most significant regulatory realignment in drug development in decades.

For those of us working at the intersection of organoid biology and translational research, this is validation of a direction we have pursued from the start. It is also a call to action.

 

What the FDA announced

The roadmap establishes a phased approach prioritizing New Approach Methodologies (NAMs) including organoids, organ-on-chip systems, AI-driven computational models, and ex vivo human tissues as alternatives to traditional animal studies. The FDA’s stated goal: make animal studies the exception rather than the norm within three to five years.

Key implementation steps already underway include a pilot program encouraging NAMs data submission alongside traditional animal data in Investigational New Drug (IND) filings, with monoclonal antibody therapies as the initial focus. In October 2025, CDER published an inventory table listing drug development contexts where the agency is open to streamlined nonclinical programs using NAMs. The agency is also developing CAMERA (Collection of Alternative Methods for Regulatory Application), a central database for validated NAMs being led by ICCVAM.

 

NIH follows with funding policy shift

In July 2025, the National Institutes of Health announced it would no longer award funding to new grant proposals solely relying on animal testing. The policy, unveiled at the joint FDA & NIH Workshop on Reducing Animal Testing, requires all new funding opportunities to incorporate language encouraging NAMs consideration alongside any proposed animal studies.

NIH plans to establish a dedicated Office of Research Innovation, Validation, and Application (ORIVA) to coordinate efforts to develop, validate, and scale non-animal approaches across the agency. This institutional commitment signals that the shift is structural, not temporary.

 

Congressional alignment: FDA Modernization Act 3.0

On April 11, 2025, Rep. Earl L. “Buddy” Carter (R-Ga.), along with Rep. Nanette Barragán (D-Calif.) and others, reintroduced the FDA Modernization Act 3.0. This bipartisan bill directs the FDA to fully implement provisions from the 2022 FDA Modernization Act 2.0 that were intended to reduce unnecessary animal testing, addressing concerns that agency implementation had lagged behind legislative intent.

 

Why this matters for organoid science

The scientific rationale is compelling. Over 90% of drugs that appear safe and effective in animals do not receive FDA approval in humans, predominantly due to safety and efficacy issues. Organoid-based assays and microphysiological systems offer superior human relevance precisely because they use human-derived cells to recapitulate aspects of tissue architecture and function that animal models cannot capture.

The FDA’s roadmap explicitly identifies three pillars of NAMs: in vitro human-derived systems (organoids, organs-on-chips), in silico approaches (AI predictive models, PBPK simulations), and innovative platforms including ex vivo human tissues. For monoclonal antibodies specifically, the agency highlights using 3D human tissue models to understand specificity and biological activity, and in vitro methods to characterize cytokine storm potential.

 

The implementation challenge

Validation remains the critical constraint. Some researchers have cautioned that most NAMs are “currently not yet ready for prime time” and that making animal studies the exception within three to five years may be “overly optimistic given the current evidence.” The pathway forward requires not only robust biological systems but also standardized protocols, harmonized data formats, and transparent quality metrics.

This is where the opportunity meets its constraint. NAMs adoption at regulatory scale demands technical excellence and cross-sector collaboration in equal measure. The FDA has acknowledged that an integrative strategy combining multiple NAMs to replace a single animal study will likely be required for many contexts of use.

 

Our perspective

At Organthis, we see this regulatory shift as confirmation of principles we have held from the start. Human-relevant models must be not only biologically sophisticated but regulatory-ready. The transition from animal testing to NAMs will not happen through policy alone. It requires infrastructure, validation frameworks, and a commitment to reproducibility that the entire field must embrace together.

The next three to five years will determine whether organoid science can meet this moment. We believe it can and we are building the systems to prove it.

 

Further reading

• FDA Press Release: Plan to Phase Out Animal Testing (April 10, 2025)
• FDA Roadmap to Reducing Animal Testing in Preclinical Safety Studies (PDF)
• CDER: Replacing and Reducing Animal Testing
• NIH: Initiative to Prioritize Human-Based Research